One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC) Three ...

The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...

Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external ...

Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external light-dark cycles.

Circadian rhythms are endogenous time-keeping mechanisms that regulate physiological processes in response to external light-dark cycles. These ...

ELF4, a transcription factor belonging to the ETS family, has emerged as a pivotal regulator in cell differentiation, immune system function, and cancer progression. This newly published review ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial ...

resulting in cell division. WNK1 was important for progression around the cycle and for bypassing checkpoints which can slow down the process, as T cells without WNK1 progressed more slowly ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced ...